Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling

[1]  Hongwei Wu,et al.  Prediction of Ticagrelor and its Active Metabolite in Liver Cirrhosis Populations Using a Physiologically Based Pharmacokinetic Model Involving Pharmacodynamics. , 2019, Journal of pharmaceutical sciences.

[2]  A. Rostami-Hodjegan,et al.  Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling , 2019, CPT: pharmacometrics & systems pharmacology.

[3]  P. Mismetti,et al.  In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition , 2018, European Journal of Drug Metabolism and Pharmacokinetics.

[4]  C. Stöllberger.  Drug interactions with new oral anticoagulants in elderly patients , 2017, Expert review of clinical pharmacology.

[5]  J. George,et al.  Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran , 2017, Antimicrobial Agents and Chemotherapy.

[6]  Deepak L. Bhatt,et al.  Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation , 2017, The New England journal of medicine.

[7]  Shannon W Finks,et al.  Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape? , 2017, The American journal of medicine.

[8]  E. Ohman,et al.  Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial , 2017, The Lancet.

[9]  C. Dézsi,et al.  Antithrombotic treatment in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention. , 2017, European journal of internal medicine.

[10]  G. Keating,et al.  Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation , 2017, Drugs.

[11]  J. Finsterer,et al.  Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs , 2016, Epilepsy Research.

[12]  B. Faller,et al.  Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery , 2016, Pharmaceutical Research.

[13]  E. Ohman,et al.  A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. , 2016, American heart journal.

[14]  P. Galajda,et al.  Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? , 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[15]  E. Ollier,et al.  In vitro and in vivo evaluation of drug–drug interaction between dabigatran and proton pump inhibitors , 2015, Fundamental & clinical pharmacology.

[16]  Z. Wang,et al.  Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention. , 2015, Contemporary clinical trials.

[17]  P. Ravindran,et al.  A Randomized Trial in Healthy Subjects to Assess the Bioequivalence of an Atazanavir/Cobicistat Fixed-Dose Combination Tablet versus Administration as Separate Agents , 2015, Antiviral therapy.

[18]  R. Teng.  Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update , 2015, Clinical Pharmacokinetics.

[19]  Sohita Dhillon.  Ticagrelor: A Review of Its Use in Adults with Acute Coronary Syndromes , 2015, American Journal of Cardiovascular Drugs.

[20]  M. Wolzt,et al.  Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects , 2014, Journal of thrombosis and haemostasis : JTH.

[21]  K. McKeage,et al.  Dabigatran Etexilate: A Review of Its Use in the Treatment of Acute Venous Thromboembolism and Prevention of Venous Thromboembolism Recurrence , 2014, Drugs.

[22]  G. Lippi,et al.  Combined Administration of Antibiotics and Direct Oral Anticoagulants: A Renewed Indication for Laboratory Monitoring? , 2014, Seminars in Thrombosis & Hemostasis.

[23]  J. Hsia,et al.  Pharmacokinetic Interaction Study of Ticagrelor and Cyclosporine in Healthy Volunteers , 2014, Clinical Drug Investigation.

[24]  Zhe-Yi Hu,et al.  Physiologically based pharmacokinetic modelling and in vivo [I]/Ki accurately predict P‐glycoprotein‐mediated drug‐drug interactions with dabigatran etexilate , 2014, British journal of pharmacology.

[25]  W. Pfeilschifter,et al.  The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation , 2013, Cerebrovascular Diseases.

[26]  J. Cairns,et al.  Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease. , 2013, The Canadian journal of cardiology.

[27]  E. Ollier,et al.  A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. , 2013, British journal of clinical pharmacology.

[28]  R. Teng,et al.  A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers , 2013, European Journal of Clinical Pharmacology.

[29]  A. Di Minno,et al.  Improving the use of direct oral anticoagulants in atrial fibrillation. , 2013, European journal of internal medicine.

[30]  M. Barclay,et al.  Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles? , 2012, British journal of clinical pharmacology.

[31]  Celeste B. Burness,et al.  Dabigatran Etexilate , 2012, Drugs.

[32]  A. Clemens,et al.  Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate , 2011, Thrombosis and Haemostasis.

[33]  F. Van de Werf,et al.  Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. , 2011, European heart journal.

[34]  M. Keltai,et al.  Coronary Heart Disease Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial , 2010 .

[35]  S. Oliver,et al.  Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects , 2010, Drug Metabolism and Disposition.

[36]  Michael Barry.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[37]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[38]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[39]  I. Abidin.  Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes , 2009 .

[40]  G. Biondi-Zoccai,et al.  Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. , 2006, European heart journal.

[41]  J. Cook,et al.  Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit , 2005, Annals of Internal Medicine.

[42]  Morton B. Brown,et al.  Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.

[43]  Kyle T. Matschke,et al.  Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects , 2016, European Journal of Clinical Pharmacology.

[44]  S. Koul,et al.  Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. , 2015, Thrombosis research.

[45]  Yu-yu Yao,et al.  Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. , 2015, Contemporary clinical trials.

[46]  J. Stangier.  Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate , 2008, Clinical pharmacokinetics.

[47]  T. Lavé,et al.  A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics , 2006, Clinical pharmacokinetics.

[48]  HighWire Press,et al.  Drug metabolism and disposition : the biological fate of chemicals. , 1973 .